Extracellular Vesicles as Drug Delivery System for Cancer Therapy
-
Published:2024-08-01
Issue:8
Volume:16
Page:1029
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Wang Jin1ORCID, Yin Bohang2, Lian Jiabing1, Wang Xia3
Affiliation:
1. School of Life Sciences, Liaoning University, Shenyang 110036, China 2. Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang 110001, China 3. Institute of Health Sciences, China Medical University, 77 Puhe Road, Shenyang 110122, China
Abstract
In recent decades, the pursuit of drug delivery systems has led to the development of numerous synthetic options aimed at enhancing drug efficacy while minimizing side effects. However, the practical application of these systems is often hindered by challenges such as inefficiency, cytotoxicity, and immunogenicity. Extracellular vesicles, natural carriers for drugs, emerge as promising alternatives with distinct advantages over synthetic carriers. Notably, EVs exhibit biocompatibility, low immunogenicity, and inherent tissue-targeting capabilities, thus opening new avenues for drug delivery strategies. This review provides an overview of EVs, including their biogenesis and absorption mechanisms. Additionally, we explore the current research efforts focusing on harnessing their potential as drug carriers, encompassing aspects such as purification techniques, drug loading, and bioengineering for targeted delivery. Finally, we discuss the existing challenges and future prospects of EVs as therapeutic agents in clinical settings. This comprehensive analysis aims to shed light on the potential of EVs as versatile and effective tools for drug delivery, particularly in the realm of cancer therapy.
Funder
Natural Science Foundation of Liaoning Province Doctor Research Initiation Program of Liaoning Province Talent Introduction Research Startup Funding of Liaoning University
Reference266 articles.
1. The Future of Drug Delivery;Gao;Chem. Mater.,2023 2. Patra, J.K., Das, G., Fraceto, L.F., Campos, E.V.R., Rodriguez-Torres, M.D.P., Acosta-Torres, L.S., Diaz-Torres, L.A., Grillo, R., Swamy, M.K., and Sharma, S. (2018). Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol., 16. 3. Nanoparticle therapeutics: An emerging treatment modality for cancer;Davis;Nat. Rev. Drug Discov.,2008 4. Thi, T.T.H., Suys, E.J.A., Lee, J.S., Nguyen, D.H., Park, K.D., and Truong, N.P. (2021). Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines, 9. 5. Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects;Maeda;Bioconjugate Chem.,2010
|
|